SHCBP1 promotes synovial sarcoma cell metastasis via targeting TGF-β1/Smad signaling pathway and is associated with poor prognosis
Open Access
- 11 October 2017
- journal article
- retracted article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 36 (1) , 1-12
Abstract
Our previous studies reported that SHC SH2-domain binding protein 1 (SHCBP1) functions as an oncogene via promoting cell proliferations in synovial sarcoma (SS) cells. However, whether SHCBP1 has any effect on tumor metastasis remains unexplored. The expression of SHCBP1 was analyzed in 76 SS tissues and two SS cell lines by immunohistochemistry and real-time RT-PCR. The relationship between SHCBP1 expression and the clinicopathological features of SS was investigated. The role of SHCBP1 in SS cell adhesion, migration, invasion and angiogenesis was explored by adhesion, Wound healing, Transwell, and Matrigel tube formation assays. Western blotting was conducted to detect the protein expressions of TGF-β1/Smad signaling pathway and EMT-related markers. The key molecules associated with migration, invasion and EMT were evaluated by immunohistochemistry in tumor specimens. In current study, we demonstrated that SHCBP1 overexpression significantly enhanced adhesion, migration, invasion and angiogenesis of SS cells. In contrast, SHCBP1 knockdown elicited the opposite effects on these phenotypes in vitro. SHCBP1 promoted tumor metastasis through inducing epithelial-mesenchymal transition (EMT) in SS cells. SHCBP1 knockdown could block the incidence of metastasis and EMT in SS cells. Furthermore, transforming growth factor-β1 (TGF-β1) induced SHCBP1 expression in a time-dependent pattern and SHCBP1 knockdown inhibited TGF-β1-induced EMT. The activation of the TGF-β1/Smad signaling pathway was involved in the oncogenic functions of SHCBP1 in SS. In addition, high expression of SHCBP1 in SS patients was associated with tumor progression and decreased survival as well as poor prognosis. Taken together, our results indicate that SHCBP1 may promote the metastasis of SS by inducing EMT through targeting TGF-β1/Smad signaling pathway and can be a potential molecular target for SS therapy.Keywords
Funding Information
- National Natural Science Foundation of China (81301727, 81301727, 81301727, 81301727, 81301727, 81301727, 81301727, 81301727, 81301727, 81301727, 81301727, 81301727, 81301727)
This publication has 38 references indexed in Scilit:
- Methyl-CpG-binding domain 3 inhibits epithelial–mesenchymal transition in pancreatic cancer cells via TGF-β/Smad signallingBritish Journal of Cancer, 2016
- SHCBP1 is over-expressed in breast cancer and is important in the proliferation and apoptosis of the human malignant breast cancer cell lineGene, 2016
- The C3G/Rap1 pathway promotes secretion of MMP-2 and MMP-9 and is involved in serous ovarian cancer metastasisCancer Letters, 2015
- Targeting SHCBP1 Inhibits Cell Proliferation in Human Hepatocellular Carcinoma CellsAsian Pacific Journal of Cancer Prevention, 2013
- The SYT-SSX fusion protein and histological epithelial differentiation in synovial sarcoma: relationship with extracellular matrix remodeling.2013
- Chromosome Instability Accounts for Reverse Metastatic Outcomes of Pediatric and Adult Synovial SarcomasJournal of Clinical Oncology, 2013
- The Aurora B-mediated phosphorylation of SHCBP1 regulates cytokinetic furrow ingressionJournal of Cell Science, 2013
- Epithelial-Mesenchymal Transitions in Development and DiseaseCell, 2009
- Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphomaLeukemia, 2009
- TGFβ in CancerCell, 2008